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Introduction
The use of the Impella device in patients with reduced left 
ventricular (LV) systolic function undergoing unprotected 
left main (LM) percutaneous coronary intervention (PCI) 
has been growing exponentially. Data from observational 
studies and registries demonstrate that Impella-assisted 
high-risk PCI is safe and effective with a low rate of peri-
procedural complications (1-3). Hemolysis is a potential 
limitation of all percutaneous mechanical circulatory 
support devices and a small incidence of hemolysis has 
also been associated with Impella use (4). The safety and 
feasibility of Impella use in patients with established pre-
existing hemolysis has not been evaluated. We report the 
case of Impella-assisted left main stem (LMS) PCI in a 
patient with severe LV systolic dysfunction and autoimmune 
hemolytic anemia (AIHA). 
Case presentation
An 82-year-old male was admitted to our institution with 
a non-ST elevation myocardial infarction (NSTEMI). 
His cardiovascular risk factors were systemic arterial 
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hypertension and a history of smoking. His medical 
background included chronic kidney disease, with a baseline 
eGFR of 40 mL/min, and myelodysplastic syndrome with 
recurrent anemia and red cell transfusion dependence. 
Blood count analysis on admission showed two-lineage 
cytopenia (hemoglobin 69 g/L, platelet count 114×109). 
Lactate dehydrogenase (LDH), bilirubin and reticulocyte 
count were all elevated while haptoglobin was reduced. 
Blood film microscopy showed features of AIHA with 
spherocytosis and polychromasia. After initial treatment 
with oral antiplatelet therapy (aspirin and clopidogrel), and 
intravenous methylprednisolone to suppress the hemolysis, 
the patient underwent coronary angiography which revealed 
severe, heavily calcified coronary artery disease involving 
the distal LM bifurcation and proximal left anterior 
descending (LAD) artery (Figure 1). An echocardiogram 
demonstrated a dilated left ventricle with global severe 
LV systolic dysfunction (ejection fraction of 32%) and a 
cardiac MRI showed viability in 16 out of 17 LV segments. 
In view of the patient’s severe comorbidities, the heart team 
concluded that the risks of surgical revascularization were 
unacceptably high, and it was decided to offer Impella-
assisted LM-PCI instead. 
Arterial access was gained via the right radial artery with 
a 7 Fr Terumo Glidesheath Slender sheath (Terumo Medical 
Corporation, Japan). A 125 cm 6 Fr pigtail catheter (Cordis, 
Fremont, California, USA) was passed to the descending 
aorta via the right radial artery and an aortogram of the 
iliac and femoral systems was obtained in order to assess 
the suitability for transfemoral Impella delivery. There 
was severe tortuosity of the right iliac artery and severe 
bilateral iliac calcification (Figure 2). The left femoral artery 
was chosen as the site of access due to less tortuosity and 
visually better dimensions for device delivery. The left 
femoral artery was punctured under fluoroscopic guidance 
using a Micropuncture Kit (Cook Medical, Bloomington, 
IN, USA) and a 14 Fr sheath (Abiomed Europe, Aachen, 
Germany) was inserted. An Impella CP (Abiomed, 
Danvers, Massachusetts, USA) was positioned in the left 
ventricle (Figure 3) and the flow was set and maintained 
at 3 L per minute. A total of 11,000 international units of 
unfractionated heparin were given and the activated clotting 
time (ACT) was monitored closely, aiming for an ACT of 
>250 s for the duration of the procedure.
PCI was performed via the right radial artery without 
complication. The LM coronary artery was engaged with a 
7 Fr EBU 3.5 guiding catheter (Medtronic Limited, MN, 
USA). A Whisper MS J-Tip guidewire (Abbott Vascular, 
Abbott, Illinois, USA) was advanced to the distal left 
circumflex artery (LCx) and an Asahi Sion black guidewire 
(Asahi Intecc Co., Ltd., Aichi, Japan) was advanced to 
the distal LAD. The LM and LAD were assessed with 
intravascular ultrasound using a Volcano IVUS catheter 
(Volcano Corporation, San Diego, California, USA). 
Following pre-dilatation of the LCx and LAD ostia and 
proximal LAD with non-compliant balloons (NC Emerge, 
Figure 2 Aortogram of the iliac and femoral system obtained by 
a pigtail catheter advanced to the descending aorta via the right 
radial artery.
Figure 1 Initial appearance of the distal LMS bifurcation. LMS, 
left main stem.
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Boston Scientific, Massachusetts, USA), the distal LM 
bifurcation was stented using the Mini-Crush technique. 
A 2.75 mm × 36 mm drug eluting stent (Biofreedom, 
Biosensors International Ltd, Singapore) was deployed in 
the LM/LAD and a 3.0 mm × 24 mm Biofreedom stent was 
deployed in the LCx. Post-dilatation was performed with a 
3.0 mm × 15 mm NC Emerge balloon in the LAD and LCx 
and a 4.0 mm × 8 mm NC Emerge balloon in the LM. Final 
kissing at the LAD/LCx bifurcation was performed with 
3.0 mm NC Emerge balloons (Figures 4,5). The Impella 
CP was removed at the end of the procedure. Femoral 
artery hemostasis was achieved using the double Angio-
Seal technique as previously described (5). Two standard 
0.035” wires were introduced through the 14 Fr femoral 
artery sheath. Following removal of the 14 Fr sheath, a 6 
Fr sheath was introduced over one wire and an 8 Fr Angio-
Seal vascular closure device (ANGIO-SEAL VIP Vascular 
Closure Device, Terumo International Systems, Somerset, 
New Jersey, USA) was deployed over the other wire. 
Following this, the 6 Fr sheath was replaced by a second 
8 Fr Angio-Seal. Radial artery hemostasis was achieved 
with a radial artery compression device (TR band, Terumo 
International Systems, Somerset, New Jersey, USA).
The Impella CP remained in situ for a total of 1 hour 
and 39 minutes. At the end of the procedure the patient 
was transferred to the coronary care unit for monitoring. 
Hemoglobin, LDH, haptoglobin and bilirubin levels were 
closely monitored with no evidence of deterioration of the 
patient’s hemolysis (Figure 6). The patient had an episode of 
epistaxis a few hours after the procedure which resolved with 
nasal packing. There was a transient hemoglobin drop on day 1 
after the procedure, which we believe was related to blood loss 
during the procedure, as well as the episode of epistaxis. The 
patient did not require any specific treatment and hemoglobin 
returned to its pre-procedure level on the following day. The 
patient was discharged home 4 days after the procedure.
Discussion
The Impella device is one of the most commonly used 
percutaneous LV assist devices and consists of a catheter-
mounted axial flow pump which is inserted in the left 
Figure 3 Final position of the Impella CP in the left ventricle.
Figure 4 Final angiographic result of Mini-Crush PCI of the distal 
LMS bifurcation in a caudal view. PCI, percutaneous coronary 
intervention; LMS, left main stem.
Figure 5 Final angiographic result in a cranial view.
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ventricle in a retrograde fashion via the femoral artery. The 
Impella CP provides a maximum flow of 4 L/min, thereby 
unloading the left ventricle throughout the cardiac cycle 
and increasing end-organ perfusion (6). The Impella 2.5 and 
Impella 5.0 provide flows of 2.5 and 5.0 L/min, respectively.
Use of the Impella device has been shown to be safe 
and effective during high-risk PCI in several publications. 
The large, multicenter, retrospective Europella registry 
demonstrated the safety and feasibility of Impella 2.5 
hemodynamic support for high-risk PCI (2). Fifty-three 
percent of the patients in the Europella registry underwent 
LM-PCI and 35% had LV systolic dysfunction. The 
30-day mortality of patients undergoing Impella assisted 
high-risk PCI was 5.5%. Similarly, results from a single 
centre retrospective evaluation of the USpella registry 
strongly supported the feasibility, safety and hemodynamic 
usefulness of the Impella device for unprotected LM 
intervention in patients with LV systolic dysfunction 
without cardiogenic shock (1). The 30-day mortality in this 
study was 2.36%. Finally, a meta-analysis of 12 studies with 
1,346 patients who underwent Impella 2.5 placement for 
support of high-risk PCI reinforced the feasibility and safety 
of Impella use in this setting with a 30-day mortality of 3.5% 
and an acceptable risk of peri-procedural complications (3).
While these data establish the safety and feasibility of 
Impella use in high-risk PCI, a small incidence of hemolysis 
has been observed in patients undergoing Impella placement 
(2,7,8). The reported incidence of hemolysis in published 
registries is 5–10% (2,7). The degree of hemolysis that has 
been observed is typically mild and resolves with removal 
of the device. Although Impella-associated hemolysis might 
contribute to the development of anemia and increased 
need for red cell transfusion, it does not appear to affect 
short-term patient outcomes or survival (9). Even in the 
rare reported cases of massive hemolysis, there appears to 
be rapid and complete resolution of hemolysis after device 
removal with no reported short-term adverse events apart 
from the need of blood transfusion (10,11).
We report the case of an Impella CP-assisted LM-PCI in 
a patient with severe LV systolic dysfunction and established 
AIHA. The patient’s bleeding risk was further increased by 
the use of high-dose steroids administered for the treatment 
of hemolysis, the presence of thrombocytopenia and the 
patient’s impaired renal function. Despite these risks, 
the procedure was carried out safely without immediate 
or short-term complications. Monitoring of markers of 
hemolysis after the procedure did not demonstrate any 
evidence of an exacerbation of the patient’s previous 
hemolysis. 
Hemolysis is a potential limitation of virtually all 
mechanical circulatory support systems (12,13). The small 
size of the Impella device, which enables percutaneous 
delivery, appears to contribute to an increased risk of 
hemolysis. Computational flow models have suggested that 
Figure 6 Pre- and post-procedure haemoglobin (Hb), platelet, bilirubin and lactate dehydrogenase (LDH) levels. Impella placement and 
PCI occurred on day 0. PCI, percutaneous coronary intervention.
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Impella-associated hemolysis is caused by the high rotatory 
shear forces of the impeller and the small clearing space 
between the impeller and its housing (14). Factors that 
appear to exacerbate hemolysis include the higher impeller 
speeds required to achieve high flow rates (15), prolonged 
duration of support (15,16) and improper positioning of the 
device (11). However, in experienced, high-volume centers 
the incidence of hemolysis is very low and clinically relevant 
hemolysis virtually never occurs. In our case, meticulous 
attention was paid to minimize modifiable factors 
potentially exacerbating the pre-existing hemolysis. More 
specifically, care was taken to position the device correctly 
in the left ventricle therefore avoiding inlet or outlet 
obstruction and the device was removed early as soon as 
hemodynamic stability was confirmed to avoid unnecessarily 
prolonged use. 
Our case demonstrates that the Impella device can 
be safely used in the context of pre-existing or ongoing 
hemolysis. Precautions should be taken to reduce all 
possible modifiable factors that can contribute to hemolysis 
and patients should be closely monitored for any clinical or 
biochemical evidence of hemolysis. 
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